GlucoTrack
GCTK
2 hedge funds and large institutions have $161K invested in GlucoTrack in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boston Financial Management
Boston,
Massachusetts
|
+$92.9K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$46.5K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
1
Boston Financial Management
Boston,
Massachusetts
| $110K | +$92.9K | +4 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $48K | +$46.5K | +2 | New |
|
3
UBS Group
Zurich,
Switzerland
| $3K | – | – | – |
|
GCTK Hedge Fund Activity: Q4 2021 in Review
2 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in GlucoTrack (GCTK) for Q4 2021, worth a combined $161K.
Buyers outnumbered sellers: 2 funds opened new GCTK positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Boston Financial Management, opening a new position worth an estimated $92.9K.
- 2 institutional investors held GlucoTrack (GCTK) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $161K of GlucoTrack stock for Q4 2021.
- 2 funds opened new GlucoTrack positions in Q4 2021 and 0 closed out, a net change of +2 holders.
- The largest GlucoTrack buyer in Q4 2021 was Boston Financial Management, an estimated $92.9K added.
Based on aggregated 13F filings for Q4 2021.